Citations

Clear

941 citation(s) found for "Tefferi, A".

Evaluation of IPSS-Revised (IPSS-R) Cytogenetic Risk Stratification and Prognostic Impact of Monosomal Karyotype in 1,014 Patients with Myelodysplastic Syndromes (MDS)
Gangat, Naseema , Patnaik, Mrinal M. , Begna, Kebede H. , Kourelius, Taxiarchis, Knudson, Ryan A., Hodnefield, Janice M., Hanson, Curtis A. , Pardanani, Animesh , Tefferi, Ayalew , Ketterling, Rhett P.

Mayo Clinic

Blood | October 9, 2019 | Volume: 120 | Issue: 21 | Pages: 423-423

10.1182/blood.v120.21.423.423 Get It

Abstract Abstract 423 Background: Cytogenetic abnormalities at diagnosis are seen in 20–70% of patients with myelodysplastic syndromes (MDS). The International Prognostic Scoring System -revised (IPSS-R) classifies these cytogenetic abnormalities into five prognostic groups: very good (del(11q), ΠY with overall survival (OS) of 61 months); good (normal, del(20q), del(5q), del(12p) with OS 49 months); intermediate (+8,7q-, i(17q),+19,+21 with OS 26 months); poor (der(3)q21/q26, −7, complex with 3 abnormalities with OS 16 months); and very poor (complex with >3 abnormalities with OS of 6 months) (Schanz J, JCO 2012, Greenberg P, Blood 2012). Monosomal karyotype (MK) is defined as the presence of two or more autosomal monosomies or a single monosomy associated with a structural abnormality. We have previously shown that MK identifies a prognostically worse subgroup of MDS patients with a complex karyotype (Patnaik M, Leukemia 2010). Objectives: Methods: The Mayo Clinic database for MDS was used to identify patients in whom bone marrow histologic and cytogenetic information was obtained at the time of diagnosis. WHO criteria were used for MDS diagnosis and leukemic transformation. Results: i) Patient characteristics: A total of 1,014 patients met the above-stipulated criteria. Median age of the cohort was 71 years (range: 18–98 years) with 684 (67%) males. 819 patients (81%) had primary MDS with 195 cases (19%) of therapy-related MDS. 759 patients (75%) are dead at a median follow-up of 18 months (range: 0–223 months) with leukemic transformation documented in 125 cases (12%). IPSS-R risk distribution was as follows: very low (n=149, 15%), good (n=261, 26%), intermediate (n=221, 22%), high (n=131, 13%), and very high (n=252, 25%). ii) IPSS-R karyotype (Entire cohort; n=1,014): The five cytogenetic groups by IPSS-R were as follows: very good (n=43, 4%), good (n=577, 57%), intermediate (n=187, 18%), poor (n=83, 8%), and very poor (n=124, 12%). We evaluated the prognostic impact of the above groups by Kaplan Meier and Cox proportional hazards analysis. OS for the five cytogenetic groups was as follows: good (36 months), very good (28 months), intermediate (20 months), poor (13 months), and very poor (6 months) (Figure 1). OS of patients with very good karyotype was significantly better than patients with very poor and poor karyotype (p<0.0001, RR 3.2 and p=0.04, RR 1.6 respectively) but similar to patients with intermediate and good karyotype (p=0.22 and 0.28 respectively). iii) IPSS-R karyotype (Primary MDS; n=819): Cytogenetic risk groups by IPSS-R were as follows: very good (n=38, 5%), good (n=512, 63%), intermediate (n=153, 19%), poor (n=46, 6%), and very poor (n=70, 9%). OS of the five groups was as follows: good (39 months), very good (23 months), intermediate (21.5 months), poor (14.5 months), and very poor (6.5 months). OS of patients with very good karyotype was significantly better than patients with very poor karyotype (p=0.0002, RR 2.5) but similar to patients with poor, intermediate and good karyotype (p=0.23, 0.26 and 0.18 respectively). iv) Monosomal karyotype: MK was identified in 153 (15%) cases of which 4 cases were intermediate, 42 poor, and 107 very poor by IPSS-R. OS of patients with MK was similar to those with very poor karyotype (6 months). In addition, OS of patients with very poor without MK was akin to patients with poor without MK (p=0.21). Furthermore, among primary MDS we identified 83 (8%) cases of MK of which 4 were intermediate, 21 were poor, and 58 very poor by IPSS-R. We confirmed that OS of patients with MK was similar to patients with very poor karyotype (6.5 months). Moreover, survival of patients with very poor without MK was similar to patients with poor without MK (p=0.51). Conclusions: In this independent analysis of 1,014 patients with MDS, IPSS-R cytogenetic risk characterization failed to discriminate between very good, good and intermediate prognostic groups. In addition, patients with very poor without MK have a similar prognosis to patients with poor without MK and should be included in the poor category whereas the presence of MK should warrant inclusion into the very poor risk category. Disclosures: No relevant conflicts of interest to declare.
Interplay Between Histone Deacetylases (HDACs) and STAT3: Mechanism of Activated JAK/STAT3 Oncogenic Pathway in ABC (Activated B-cell) Type Diffuse Large B Cell Lymphoma.
Stenson, Mary, Lasho, Terra, Tefferi, Ayalew , Novak, Anne J. , Ansell, Stephen M. , Gupta, Mamta , Lasho, Terra, Witzig, Thomas E.

Mayo Clinic

Blood | October 9, 2019 | Volume: 114 | Issue: 22 | Pages: 925-925

10.1182/blood.v114.22.925.925 Get It

Abstract Abstract 925 Diffuse large B-cell lymphomas (DLBCL) consists of biologically distinct subtypes: Germinal Center B-cell (GCB)–like and Activated B-cell (ABC)-like. Studies to date suggest that patients with tumors that have ABC features have an inferior survival; therefore, it is important to develop new therapies specifically for ABC-type DLBCL based on mechanistic differences. It has been shown that the ABC-DLBCL has high levels of total and phosphorylated STAT3 (pSTAT3) protein and this STAT3 activity may play a role in the survival of ABC-DLBCL cells. Indeed, when ABC and GCB cell were incubated with the novel JAK2 inhibitor TG101348 (TargeGen, San Diego, CA) we found potent cytotoxicity (LD50 2μM) in ABC DLBCL but not in GCB DLBCL. This provides further rationale to study the regulation of STAT3 in the survival of ABC type DLBCL cells. In studies of HDAC expression in ABC DLBCL cells, we found over-expression of the class 1 histone deacetylases, specifically HDAC1 and HDAC3. We then performed co-immunoprecipitation experiments to learn the functional interaction between STAT3 and HDACs. We found that STAT3 formed complexes with HDAC1 to a greater extent than HDAC3. We also showed that STAT3 did co-precipitate with HDAC1 suggesting a reciprocal relationship between these two proteins. These results suggested that HDAC1 (but not HDAC3) might be involved in the regulation of STAT3. The HDAC inhibitor LBH589 (LBH, Novartis Pharm) was more cytotoxic to ABC (LD50, 10-20nM) than GCB (LD50, 50-100nM) and was shown to dephosphorylate STAT3. These results led to experiments designed to determine the effect of LBH on STAT3 acetylation. When ABC cells were incubated with LBH, co-immunoprecipitation data showed a dose-dependent increased in acetylation of STAT3 without significant change on the levels of STAT3 immunoprecipitated. Next, we asked that how LBH is dephosphorylating STAT3. One potential mechanism is activation of a protein phosphatase. Immunoprecipitation of protein phosphatase 2A (PP2A) in the lysates of LBH-treated cells followed by western blotting of STAT3 demonstrated a positive correlation between LBH dose and amount of STAT3 co-immunoprecipitated with PP2A. Our data show that when LBH is incubated with ABC cells, the LBH increases binding of PP2A to STAT3 and the increased phosphatase activity turns off STAT3 signaling. Since both HDAC inhibitor (LBH) and the JAK2 inhibitor (TG) had selective cytotoxic effects on ABC cells, and since both agents dephosphorylate STAT3, we combined the two drugs. We found that the combination exhibited enhanced inhibitory effects on the growth of ABC cells and was able to alter the association of STAT3 with HDAC1 and subsequently dephosphorylate STAT3 to greater extent than either agent alone. Furthermore, we knocked down HDAC1 expression (through siRNA) in OCILy10 (ABC) cells and showed that inhibition of HDAC1 inhibits constitutively activated STAT3. This data suggests that inhibiting HDAC1 expression results in STAT3 dephosphorylation. In summary, we have demonstrated that a key consequence of HDAC expression in ABC cells is continuous activation of STAT3. These data indicate that HDACs activate STAT3 and that PP2A may be important in maintaining STAT3 in the activated state in the ABC cells. This study describes a new mechanism by which STAT3 mediates ABC cell survival and provides the rationale for targeting ABC type DLBCL by simultaneously inhibiting HDAC activity and STAT3 activation by pharmacologic grade inhibitors such as LBH589 and TG101348, which are currently in clinical trial. A phase 1 and 2 trial of JAK2 inhibitor, TG101348 for ABC/GCB type DLBCL is planned. Disclosures: No relevant conflicts of interest to declare.
Survival and Prognosis in World Health Organization Defined Chronic Myelomonocytic Leukemia- A Mayo Clinic Series of 227 Patients
Patnaik, Mrinal M. , Hanson, Curtis A. , Hodnefield, Janice M., Knudson, Ryan A., Pardanani, Animesh , Tefferi, Ayalew , Ketterling, Rhett P.

Mayo Clinic

Blood | October 9, 2019 | Volume: 120 | Issue: 21 | Pages: 3790-3790

10.1182/blood.v120.21.3790.3790 Get It

Abstract Abstract 3790 Background: Chronic myelomonocytic leukemia (CMML) is a clonal stem cell disorder characterized by: persistent peripheral blood (PB) monocytosis (>1 × 10(9)/L), absence of BCR-ABL1 fusion, absence of rearrangement of the PDGFRA/B genes, <20% bone marrow (BM) & PB blasts, and dysplasia involving one or more myeloid cell lines. It is clinically considered to be an overlapping syndrome with myelodysplastic and myeloproliferative features. The natural history and prognostic features of CMML are not well defined with the MD Anderson prognostic score (MDAPS) and the Spanish risk stratification by cytogenetics being the two major prognostic tools currently being used in clinical practice. Methods: 227 patients with WHO defined CMML were seen at the Mayo Clinic from 1997 through 2007. All patients underwent bone marrow (BM) examination and cytogenetic evaluation at diagnosis. We evaluated the prognostic relevance of several clinical and laboratory parameters including those previously identified by the MDAPS (Blood 2002;99:840) and the Spanish cytogenetic risk stratification (Haematologica 2011;96:375). Results: Among the 227 study patients, 153 (67%) were males and median age was 71 years (range, 17–90 years). There were 192 (85%) patients with CMML-1 & the remainder had CMML-2. At a median follow-up of 15 months, 166 (73%) deaths and 33 (14.5%) leukemic transformations were documented. Median survivals were 22 months for CMML-1 and 14 months for CMML-2. In univariate analysis, significant risk factors for survival included decreased hemoglobin level, decreased platelet count and increased levels of white blood cells (WBC), absolute neutrophils (ANC), absolute monocytes (AMC), absolute lymphocytes (ALC), PB blasts, BM blasts and presence of circulating immature myeloid cells (IMC; inclusive of PB blasts). However, on multivariable analysis that included the aforementioned Spanish cytogenetic risk stratification, only increased AMC (>10 × 10(9)/L, RR 2.5, 95% CI 1.7–3.8), presence of circulating IMC (RR 2.0, 95% CI 1.4–2.7), decreased hemoglobin (<10 g/dL; RR 1.6, 99% CI 1.2–2.2), and decreased platelet count (<100 × 10(9)/L; RR 1.4, 99% CI 1.0–1.9) retained significance. Using these four independent risk factors, we prepared a new prognostic risk model that performed better than both the MDAPS and the Spanish cytogenetic risk models (Figure). The Mayo risk model was also predictive of leukemic transformation: high risk RR 4.9 (95% CI 1.9–12.8) and intermediate risk RR 2.6 (1.1–5.9). Individual parameters of independent significance for leukemic transformation included PB blast count and AMC >10 × 10(9)/L. Conclusions: Absolute monocyte count is the strongest predictor of survival in CMML. Other independent risk factors include circulating immature myeloid cells, anemia and thrombocytopenia. A risk model based on these four risk factors is effective in predicting both overall and leukemia-free survival and outperforms both the MDAPS and risk stratification by cytogenetics. Disclosures: No relevant conflicts of interest to declare.
Long-Term Follow up and Optimized Dosing Regimen of INCB018424 in Patients with Myelofibrosis: Durable Clinical, Functional and Symptomatic Responses with Improved Hematological Safety.
Pardanani, Animesh , Thomas, Deborah A. , Bradley, Edward C., Erickson‐Viitanen, Susan, Vaddi, Kris , Tefferi, Ayalew , Verstovšek, Srđan , Kantarjian, Hagop M. , Mesa, Ruben A. , Cortes, Jörge E. , Estrov, Zeev E. , Levy, Richard

Mayo Clinic

Blood | October 9, 2019 | Volume: 114 | Issue: 22 | Pages: 756-756

10.1182/blood.v114.22.756.756 Get It

Abstract Abstract 756 Background: Myelofibrosis (MF) is the most serious of chronic myeloproliferative neoplasms (MPNs) for which there is no approved therapy. Exaggerated JAK2 signaling, either by gain-of-function mutations (eg, JAK2V617F) or high circulating levels of JAK1/2 activating cytokines (eg, interleukin [IL]-6), is believed to play a key role in MPN pathogenesis. INCB018424 (424), a selective oral inhibitor of JAK1/2, has demonstrated clinical benefits including reduction of splenomegaly and improvement of symptoms in a Phase I/II trial in MF patients. Thrombocytopenia was identified as the dose limiting toxicity occurring in 30% of patients at 25mg BID. Methods: Patients with primary, post-PV or post-ET MF were enrolled in the study. Following the characterization of multiple dosing regimens, an individually optimized dose regimen strategy was developed, based on available efficacy and safety data. In a subset of patients, spleen volume change was measured by MRI at 1, 3 and 6 months of treatment in order to establish an objective measure of spleen response. The impact of 424 on MF associated symptoms was assessed using a validated instrument, MFSAF (Mesa et al., Leukemia Research 2009). As a surrogate marker of functional benefit, exercise capacity was assessed with a standardized 6-minute walk test (6MWT) at baseline, 1, 3 and 6 months of therapy. Results: 155 patients were enrolled in the study, with median duration of treatment of 1+ years and the duration of drug exposure of >150 patient years (76 patients received >1 year of therapy). Clinical responses have been maintained over the entire duration of treatment and most patients remain on therapy (115 of 155 patients; 74%). Progression to AML occurred in 3 patients, which is below the expected frequency based on published data (Barosi et al., Blood 2007). SAEs related to 424 occurred in 12 patients, and are generally related to bone marrow suppression or return of or exacerbation of signs and symptoms of MF when therapy is discontinued. Further optimization of the dosing regimen utilized baseline platelet count to determine the starting dose (10 or 15mg BID) and allowed dose titration after 1 and 2 months of therapy; most patients were optimized to 15 or 20mg BID. This approach significantly reduced the incidence of thrombocytopenia (<5%, N=35), while providing equivalent efficacy to higher dose regimens. With an optimized dosing regimen, spleen volume reduction was evident as early as 1 month, and durable over 6 months, of therapy (33 % median decrease after 6 months, N=23). Eleven of 23 (48%) of patients achieved ≥ 35% reduction (equivalent to IWG clinical improvement criteria of 50% reduction by palpation) from baseline in spleen volume at month 6. MF patients have impaired exercise capacity at baseline (decreased 6MWT performance by 60-90 meters vs. age-matched controls). Treatment with 424 resulted in improved 6MWT performance, with median increase from baseline of 33, 58 and 70 meters after 1,3 or 6 months of therapy, respectively. Rapid and durable reduction of a total symptom score based on key symptoms (fatigue, abdominal discomfort/pain, bone/muscle pain, night sweats and pruritus) was noted (51 % and 58% of patients achieving 50% reduction in the total score following 1 and 6 months of treatment, respectively). Improvement in symptoms coincided with a rapid and sustained reduction in pro-inflammatory cytokines, including IL-1b, IL-1ra, IL-6 and TNFa, without tachyphylaxis to therapy. Finally, spleen response was associated with greater improvements in total symptom score, exercise capacity, and reduced fatigue (see Table). Conclusion: An optimized dosing regimen of INCB018424 resulted in sustained clinical, symptomatic and functional benefits in MF patients with an improved hematological safety profile compared to a 25 mg BID regimen. Safety and efficacy of 424 in MF patients is further supported by the follow-up data of >1 yr of 424 therapy. Disclosures: Verstovsek: Incyte: Research Funding. Bradley:Incyte Corporation: Employment, Equity Ownership. Erickson-Viitanen:Incyte Corporation: Employment, Equity Ownership. Vaddi:Incyte Corporation: Employment, Equity Ownership. Levy:Incyte Corporation: Employment, Equity Ownership.
PF668 RESULTS FROM ONGOING PHASE 1/2 CLINICAL TRIAL OF TAGRAXOFUSP (SL‐401) IN PATIENTS WITH INTERMEDIATE, OR HIGH RISK, RELAPSED/REFRACTORY MYELOFIBROSIS
Pemmaraju, Naveen , Ali, Haris , Yacoub, Abdulraheem , Schiller, Gary J. , Lee, S. , Wang, E., Sardone, Megan, Wysowskyj, Halyna, Shemesh, Shay , Chen, J., Brooks, Cassandra, Poradosu, Enrique, Rupprecht, Nicole, Pardanani, Animesh , Tefferi, Ayalew , Khoury, Joseph D. , Patnaik, Mrinal M. , Gupta, Vikas , Talpaz, Moshe , Taparia, Minakshi , McDonald, P., Verstovšek, Srđan

Mayo Clinic

HemaSphere | June 17, 2019 | Volume: 3 | Issue: S1 | Pages: 286-287

10.1097/01.hs9.0000560956.60646.c2 Get It

Background:Patients with myelofibrosis (MF) who fail or are intolerant to JAK inhibitors (JAKi) have limited treatment options. Tagraxofusp is a targeted therapy directed to CD123 that was approved by the US FDA for the treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). CD123 is expressed on a variety of malignancies including BPDCN, acute myeloid leukemia (AML), and certain myeloproliferative neoplasms (MPN), including MF. Moreover, CD123+ plasmacytoid dendritic cells (pDCs), the cell of origin of BPDCN, have been detected in the microenvironment of certain myeloid neoplasms, including MF, where they may play a tumor‐promoting role.1,2,3 Notably, pDCs share a common precursor cell with monocytes, and monocytosis has been reported as a poor prognostic factor, associated with rapid disease progression and shortened survival, suggesting an accelerated disease phase in MF.4 As such, tagraxofusp may offer a novel and rational therapeutic approach in patients with relapsed/refractory MF, including patients with monocytosis.Aims:Primary objectives include assessment of safety, determining the recommended Phase 2 dose (RP2D) and schedule, and evaluating efficacy in patients with MF who were relapsed, refractory, or unable to tolerate JAKi.Methods:This multicenter, open‐label Phase 1/2 trial is enrolling patients with MF. In the Stage 1 (dose escalation), tagraxofusp was administered as a daily IV infusion at 7, 9, and 12 mcg/kg on days 1–3 every 21 days (cycle 1–4), 28 days (cycles 5–7), and 42 days (cycles 8+). In Stage 2 (expansion), patients are receiving the RP2D (12 mcg/kg).Results:23 patients with MF received tagraxofusp, including 12 patients who received ≥ 3 prior lines of therapy. Median age 69 years (range 55–81), 61% were female, and 30% had baseline monocytosis (≥ 1x109/L). Baseline risk assessment based on the DIPSS Plus risk group assessment showed 1 patient (4%) with intermediate‐1, 12 patients (52%) with intermediate‐2, and 10 patients (44%) with high‐risk. At study entry, the median platelet count was 59 K/uL with 71% of patients had baseline platelets <100 K/uL, of which 8 patients had platelets <50 K/uL. 87% of patients had baseline splenomegaly (spleen palpable ≥ 5 cm below the left costal margin [LCM]). Most common treatment‐related adverse events (TRAEs, incidence ≥ 15%) include headache, hypoalbuminemia, alanine aminotransferase increased and thrombocytopenia. The most common ≥ grade 3 TRAE was thrombocytopenia (8%). Capillary leak syndrome was reported in 1 patient (grade 3). Among the 14 evaluable patients with baseline splenomegaly, 57% had spleen size reductions: 43% (6/14) had reductions of > 25%, of which 3 patients had reductions of ≥ 45%. In 5 patients with baseline splenomegaly and monocytosis, 80% (4/5) had reductions of > 25%, of which 2 had reductions of ≥ 45%. Six patients, including 3 patients with monocytosis and 5 patients with platelets <100 K/uL, had treatment duration of 6 months or more.Summary/Conclusion:Tagraxofusp demonstrated single agent activity, with a predictable and manageable safety profile, in patients with relapsed/refractory MF, including in patients with monocytosis, a poor prognostic factor, both constituting potential areas of unmet medical need. Enrollment continues, and updated trial data will be presented. Registrational trial designs are being evaluated. Trial information: NCT02268253.
PF672 RESULTS FROM ONGOING PHASE 1/2 CLINICAL TRIAL OF TAGRAXOFUSP (SL‐401) IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)
Patnaik, Mrinal M. , Ali, Haris , Yacoub, Abdulraheem , Schiller, Gary J. , Lee, S., Wang, E., Sardone, Megan, Wysowskyj, Halyna, Shemesh, Shay , Chen, J., Brooks, Cassandra, Poradosu, Enrique, Rupprecht, Nicole, Pardanani, Animesh , Tefferi, A, Khoury, Julie, Pemmaraju, Naveen , Gupta, Vikas , Talpaz, Moshe , Wang, E., Taparia, Minakshi , McDonald, P., Verstovšek, Srđan , Khoury, J.

Mayo Clinic

HemaSphere | June 17, 2019 | Volume: 3 | Issue: S1 | Pages: 289

10.1097/01.hs9.0000560972.91141.2d Get It

Background:Patients with chronic myelomonocytic leukemia (CMML) have historically poor outcomes, with ∼6–7 month median overall survival (OS) in the relapsed/refractory (r/r) setting. Splenomegaly is a major cause of morbidity, is a poor prognostic factor and has emerged as a potential therapeutic target in CMML. Tagraxofusp (SL‐401) is a targeted therapy directed to CD123, a target expressed on CMML blasts, monocytes and neoplastic microenvironmental plasmacytoid dendritic cells (pDCs) that are part of the CMML malignant clone, as well as on a variety of additional malignancies. Tagraxofusp was approved by the US FDA for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) and is being investigated in other CD123‐expressing malignancies.Aims:Primary objectives include assessment of safety, determining the recommended Phase 2 dose (RP2D) and schedule, and evaluating efficacy in patients with CMML.Methods:This multicenter, open‐label, Phase 1/2 clinical trial is enrolling patients with CMML. In Stage 1 (dose escalation), tagraxofusp was administered as a daily IV infusion at 7, 9, and 12 mcg/kg on days 1–3 every 21 days (cycle 1–4), every 28 days (cycles 5–7), and every 42 days (cycles 8 and beyond). In Stage 2 (expansion), patients receive the RP2D (12 mcg/kg).Results:20 patients with CMML (CMML‐1 [n = 12]; CMML‐2 [n = 8]) were treated with tagraxofusp, including 18 in the relapsed/refractory setting, with hypomethylating agents (HMAs) being the most commonly administered prior therapy. Median age was 69 years (range 43–80) and 80% were male. 10 patients (50%) had baseline splenomegaly (defined as spleen palpable below the left costal margin [BCM]), of which 6 had baseline splenomegaly ≥ 5 cm BCM. Most common treatment‐related adverse events (TRAEs, incidence ≥ 20%) were hypoalbuminaemia, thrombocytopenia, nausea, vomiting and fatigue. Most common ≥ grade 3 TRAEs were thrombocytopenia (35%) and nausea (5%). Capillary leak syndrome was reported in 3 patients (grade 1–2). 100% (10/10) of patients with baseline splenomegaly had a spleen response by physical exam: 80% (8/10) had spleen size reduction of ≥ 50% and 67% (4/6) with baseline spleen size ≥ 5 cm had spleen size reduction of ≥ 50%. Three patients treated with tagraxofusp achieved bone marrow complete responses (BMCRs), including 1 patient who was bridged to stem cell transplant in remission on tagraxofusp.Summary/Conclusion:Tagraxofusp demonstrated single agent activity in patients with CMML and splenomegaly, an area of potential unmet medical need. Given the expression of CD123 in CMML, tagraxofusp represents a rational therapeutic approach in this disease. Updated data will be presented, and a registrational trial is planned. Trial information: NCT02268253.
Germline SH2B3 pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
Coltro, Giacomo , Finke, Christy M. , Gangat, Naseema , Pardanani, Animesh , Tefferi, Ayalew , Jevremović, Dragan , Altman, Jessica K. , Patnaik, Mrinal M. , Lasho, Terra L. , Gangat, Naseema , Tefferi, Ayalew , Patnaik, Mrinal , Jevremovic, Dragan

Mayo Clinic

American Journal of Hematology | June 7, 2019 | Volume: 94 | Issue: 9 | Pages: No page available

10.1002/ajh.25552 | PMID 31173385 Get It

Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial
Gangat, Naseema , Marinaccio, Christian , Swords, Ronan , Watts, Justin M. , Rademaker, Alfred , Fought, Angela J. , Frankfurt, Olga, Altman, Jessica K. , Wen, Qiang , Farnoud, Noushin , Famulare, Christopher , Patel, Akshar, Vallapureddy, Rangit, Barath, Stephanie, Graf, Amy, Handlogten, Amy, Zblewski, Darci, Patnaik, Mrinal M. , Al‐Kali, Aref , Dinh, Yvonne, Prahl, Kristen Englund, Patel, Shradha, Nobrega, Juan Carlos , Tejera, Dalissa, Thomassen, Amber , Gao, Juehua , Rampal, Raajit K. , Tefferi, Ayalew , Stein, Brady L. , Crispino, John D. , Vallapureddy, Rangit R, Rampal, Raajit K , Giles, Francis Joseph , Crispino, John D , Gurbuxani, Sandeep K. , Wen, Qiang Jeremy, TAPIA-CONYER, ROBERTO C. , Ji, Peng Cheng

Mayo Clinic

Clinical Cancer Research | May 7, 2019 | Volume: 25 | Issue: 16 | Pages: 4898-4906

10.1158/1078-0432.ccr-19-1005 | PMID 31061068 Get It

Abstract Purpose: Myelofibrosis is characterized by bone marrow fibrosis, atypical megakaryocytes, splenomegaly, constitutional symptoms, thrombotic and hemorrhagic complications, and a risk of evolution to acute leukemia. The JAK kinase inhibitor ruxolitinib provides therapeutic benefit, but the effects are limited. The purpose of this study was to determine whether targeting AURKA, which has been shown to increase maturation of atypical megakaryocytes, has potential benefit for patients with myelofibrosis. Patients and Methods: Twenty-four patients with myelofibrosis were enrolled in a phase I study at three centers. The objective of the study was to evaluate the safety and preliminary efficacy of alisertib. Correlative studies involved assessment of the effect of alisertib on the megakaryocyte lineage, allele burden, and fibrosis. Results: In addition to being well tolerated, alisertib reduced splenomegaly and symptom burden in 29% and 32% of patients, respectively, despite not consistently reducing the degree of inflammatory cytokines. Moreover, alisertib normalized megakaryocytes and reduced fibrosis in 5 of 7 patients for whom sequential marrows were available. Alisertib also decreased the mutant allele burden in a subset of patients. Conclusions: Given the limitations of ruxolitinib, novel therapies are needed for myelofibrosis. In this study, alisertib provided clinical benefit and exhibited the expected on-target effect on the megakaryocyte lineage, resulting in normalization of these cells and reduced fibrosis in the majority of patients for which sequential marrows were available. Thus, AURKA inhibition should be further developed as a therapeutic option in myelofibrosis. See related commentary by Piszczatowski and Steidl, p. 4868
Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients
Coston, Tucker , Pophali, Prateek , Vallapureddy, Rangit, Finke, Christy M. , Binder, Moritz , Mangaonkar, Abhishek A. , Gangat, Naseema , Al‐Kali, Aref , Litzow, Mark R. , Zblewski, Darci, Pardanani, Animesh , Tefferi, Ayalew , Patnaik, Mrinal M. , Lasho, Terra L. , Carr, Ryan, Binder, Moritz , Mangaonkar, Abhishek A. , Gangat, Naseema , Litzow, Mark R. , Tefferi, Ayalew , Patnaik, Mrinal , Ketterling, Rhett P. , Carr, Ryan M

Mayo Clinic

American Journal of Hematology | April 9, 2019 | Volume: 94 | Issue: 7 | Pages: 767-779

10.1002/ajh.25488 | PMID 30964202 Get It

AbstractHypomethylating agents (HMA) are currently the only FDA approved therapy for patients with chronic myelomonocytic leukemia (CMML). In the current retrospective study, we assessed response rates as adjudicated by the IWG (International Working Group) MDS (myelodysplastic syndrome) and MDS/MPN myeloproliferative neoplasm overlap syndrome response criteria, in 121 CMML patients treated with Azacitidine (AZA, n = 56) and Decitabine (DAC, n = 65). The overall response rates were 41% by the IWG MDS (AZA‐ 45%, DAC‐39%), and 56% by the IWG MDS/MPN (AZA‐56%, DAC‐58%) response criteria, with CR (complete remission) rates of <20% for both agents, by both criteria. There were no significant differences in response rates between proliferative and dysplastic CMML. Moreover, 29% of CMML patients in a CR with HMA progressed to AML (blast transformation), underscoring the limited impact of these agents on disease biology. Progression after HMA response was associated with a median overall‐survival (OS) of 8 months, while median OS in patients with primary HMA failure was 4 months. Lower serum LDH levels (<250 Units/L) were associated with HMA responses by both criteria; while ASXL1 and TET2 mutational status had no impact. HMA treated patients had a longer median OS (31 vs 18 months; P = .01), in comparison to those treated with conventional care regimens (excluding observation only patients), without any differences between AZA vs DAC (P = .37). In conclusion, this study highlights the inadequacies of HMA therapy in CMML, retrospectively validates the IWG MDS/MPN response criteria and underscores the need for newer, rationally derived therapies.
Comments on pre‐fibrotic myelofibrosis and how should it be managed
Barbui, Tiziano , Thiele, Jüergen, Gisslinger, Heinz , Orazi, Attilio , Gianelli, Umberto , Beham‐Schmid, Christine, Tefferi, Ayalew , Tefferi, Ayalew , Gianelli, Umberto , Orazi, Attilio , Vannucchi, Alessandro M.

Mayo Clinic

British Journal of Haematology | March 8, 2019 | Volume: 186 | Issue: 2 | Pages: 358-360

10.1111/bjh.15840 | PMID 30847907 Get It